Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated statements provided align with the supplied FDA label excerpts for thyroid C-cell tumor risk, human relevance being unknown, and contraindications for personal/family history of MTC or MEN 2.
Category Scores
Accurate Statements
WEGOVY/semaglutide has a risk of thyroid C-cell tumors (including MTC); it is unknown in humans.
Supported by 5.1 Risk of Thyroid C-Cell Tumors: semaglutide caused dose- and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) in mice and rats; it states it is unknown whether WEGOVY causes thyroid C-cell tumors, including MTC, in humans.
WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Supported by 4 Contraindications and cross-referenced to 5.1: contraindicated in personal or family history of MTC or MEN 2.
Unsupported Statements
Contradictions
Important Omissions
The AI excerpted claim did not include the label’s details about patient counseling and specific symptom examples (e.g., neck mass, hoarseness, dysphagia, dyspnea) or the statements about routine calcitonin/thyroid ultrasound monitoring being of uncertain value.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim correctly reflects the boxed/sectioned warning about thyroid C-cell tumor risk with unknown human relevance and the contraindication for MTC/MEN 2; no contradictions were identified in the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of specific patient counseling and monitoring/diagnostic details found in the label’s thyroid C-cell tumor warning section.
Suggested Improvement
If communicating the warning, include the label’s counseling symptom examples and/or the statement that routine calcitonin/thyroid ultrasound monitoring is of uncertain value, as applicable to the context.